Selection of MicroRNAs Associated between Neural Stem Cells and Multiple Sclerosis
Abstract
Background: Diagnosis and treatment of multiple sclerosis (MS) in its advanced state have been one of the medical community's concerns so far. Cell therapy has been a modern and successful treatment. However, it has not yet been effective enough to treat MS. This study aimed to find the relationship between neural stem cells (NSCs) and MS, and by considering important signaling pathways of pathogenesis, the most important microRNAs (miRNAs) for its diagnosis and treatment were investigated. Materials and Methods: Using the bioinformatics approaches and appropriate databases, the relationship between NSCs and MS were recognized, and after obtaining common genes between them, the protein products by them were evaluated. Finally, after nominating essential genes, we isolated and analyzed the microarrays involved in these pathways. Results: In the first step, 76 upregulated and 1600 down-regulated common genes between NSCs and MS were recognized. Upregulated genes obtained axon guidance, NCAM, and RHO signaling pathways, and the cell cycle, RNA metabolism, and DNA repair signaling pathways by down-regulated genes. Then, high-expression PAK3, ROBO2, and LIMK2, and low-expression AURKA, BIRC5, BLM, and BRCA1 proteins were identified. Accordingly, high-expression miRNAs included hsa-miR-4790-5p, hsa-miR-4281, and hsa-miR-4327, but low-expression miRNAs included hsa-miR-103b, hsa-miR-638, and hsa-miR-4537 were recognized. Conclusion: Our study indicated that the abovementioned important miRNAs have a major role in diagnosing and treating MS.References
Kobelt G, Thompson A, Berg J, Gannedahl M, Eriksson J, MSCOI Study Group, et al. New insights into the burden and costs of multiple sclerosis in Europe. Mult Scler J. 2017;23(8):1123-36.
https://doi.org/10.1177/1352458517694432
PMid:28273775 PMCid:PMC5476197
Kaisey M, Solomon AJ, Mph ML, Giesser BS, Sicotte NL. Incidence of multiple sclerosis misdiagnosis in referrals to two academic centers. Mult Scler Relat Disord. 2019;30:51-6.
https://doi.org/10.1016/j.msard.2019.01.048
PMid:30738280
Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, et al. diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2017;17(2):162-73.
https://doi.org/10.1016/S1474-4422(17)30470-2
PMid:29275977
Scolding NJ, Pasquini M, Reingold SC, Cohen JA, Atkins H, Banwell B, et al. Cell-based therapeutic strategies for multiple sclerosis Immunoablation followed by haematopoietic stem cell. Brain. 2017;140(11):2776-96.
https://doi.org/10.1093/brain/awx154
PMid:29053779 PMCid:PMC5841198
Zhang C, Cao J, Li X, Xu H, Wang W, Wang L, et al. Treatment of multiple sclerosis by transplantation of neural stem cells derived from induced pluripotent stem cells. Sci China Life. 2016;59(9):950-7.
https://doi.org/10.1007/s11427-016-0114-9
PMid:27233903
Pluchino S, Martino G. Pluchino S, Martino G. The therapeutic plasticity of neural stem/precursor cells in multiple sclerosis. J Neurol Sci. 2008;265:105-10.
https://doi.org/10.1016/j.jns.2007.07.020
PMid:17706971
Thompson AJ. Challenge of progressive multiple sclerosis therapy. Curr Opin Neurol. 2017;30(3):237-40.
https://doi.org/10.1097/WCO.0000000000000453
PMid:28338498
Tutunchi S, Akhavan S, Bereimipour A, Hossein Ghaderian SM. Evaluation of Important Molecular Pathways and Candidate Diagnostic Biomarkers of Noninvasive to Invasive Stages in Gastric Cancer by In Silico Analysis. J Oncol. 2021;2021:5571413.
https://doi.org/10.1155/2021/5571413
PMid:34054953 PMCid:PMC8131151
Mirzaei M, Sheikholeslami SA, Jalili A, Bereimipour A, Sharbati S, Kaveh V, Salari S. Investigating the molecular mechanisms of Tamoxifen on the EMT pathway among patients with breast cancer. J Med Life. 2022;15(6):835-44.
https://doi.org/10.25122/jml-2022-0085
PMid:35928368 PMCid:PMC9321501
Liu M, Hou X, Zhang P, Hao Y, Yang Y, Wu X, et al. Microarray gene expression profiling analysis combined with bioinformatics in multiple sclerosis Microarray gene expression profiling analysis combined with bioinformatics in multiple sclerosis. Mol Biol. 2013;40(5):3731-7.
https://doi.org/10.1007/s11033-012-2449-3
PMid:23456643
Islam T, Rahman MR, Karim MR, Huq F, Quinn JM, Moni MA. Unlocked Detection of multiple sclerosis using blood and brain cells transcript pro fi les: Insights from comprehensive bioinformatics approach. Informatics Med Unlocked. 2019;16:100201.
https://doi.org/10.1016/j.imu.2019.100201
Grochowski C, Radzikowska E, Maciejewski R. Neural stem cell therapy-Brief review. Clin Neurol Neurosurg. 2018;1(173):8-14.
https://doi.org/10.1016/j.clineuro.2018.07.013
PMid:30053745
Fri D, Korchak JA, Zubair AC. Challenges and translational considerations of mesenchymal stem / stromal cell therapy for Parkinson ' s disease. NPJ Regen Med. 2020;3(5):1-10.
https://doi.org/10.1038/s41536-020-00106-y
PMid:33298940 PMCid:PMC7641157
Greenfield AL, Hauser SL, Francisco S. B‐cell Therapy for Multiple Sclerosis: Entering an era. Ann Neurol. 2019;83(1):13-26.
https://doi.org/10.1002/ana.25119
PMid:29244240 PMCid:PMC5876115
Bonab MM, Sahraian MA, Aghsaie A, Karvigh SA, Hosseinian SM, Nikbin B, et al. Autologous Mesenchymal Stem Cell Therapy in Progressive Multiple Sclerosis: An Open Label Study. Curr Stem Cell Res Ther. 2012;7(6):407-14.
https://doi.org/10.2174/157488812804484648
PMid:23061813
Kular L, Needhamsen M, Adzemovic MZ, Kramarova T, Gomez-cabrero D, Ewing E, et al. Neuronal methylome reveals CREB- associated neuro-axonal impairment in multiple sclerosis. Clin Epigenetics. 2019;11(1):1-20.
https://doi.org/10.1186/s13148-019-0678-1
PMid:31146783 PMCid:PMC6543588
Mulero P, Córdova C, Hernández M, Martín R, Gutiérrez B, Muñoz JC, et al. Netrin-1 and multiple sclerosis: a new biomarker for neuroinflammation? Eur J Neurol. 2017;24(9):1-8.
https://doi.org/10.1111/ene.13340
PMid:28677863
Chu C, Gao Y, Lan X, Thomas A, Li S. NCAM Mimetic Peptides: Potential Therapeutic Target for Neurological Disorders. Neurochem Res.2018;43(9):1714-22.
https://doi.org/10.1007/s11064-018-2594-8
PMid:30003388
Ziliotto N, Zivadinov R, Jakimovski D, Baroni M, Tisato V, Secchiero P, et al. Plasma levels of soluble NCAM in multiple sclerosis. J Neurol Sci. 2019;396:36-41.
https://doi.org/10.1016/j.jns.2018.10.023
PMid:30412901
Huang GH, Sun ZL, Li HJ, Feng DF. Molecular and Cellular Neuroscience Rho GTPase-activating proteins: Regulators of Rho GTPase activity in neuronal development and CNS diseases. Mol Cell Neurosci. 2017;80:18-31.
https://doi.org/10.1016/j.mcn.2017.01.007
PMid:28163190
Groot M, Lee H. Sorting Mechanisms for MicroRNAs into Extracellular Vesicles and Their Associated Diseases. Cells. 2020;9(4):1-16.
https://doi.org/10.3390/cells9041044
PMid:32331346 PMCid:PMC7226101
Maillart E. Multiple Sclerosis on behalf SFSEP Treatment of progressive multiple sclerosis: Challenges and promising perspectives. Rev Neurol. 2018:1-8.
Bame M, McInnis MG, O'Shea KS. MicroRNA alterations in induced pluripotent stem cell-derived neurons from bipolar disorder patients: pathways involved in neuronal differentiation, axon guidance, and plasticity. Stem Cells Dev. 2020;29(17):1145-59.
https://doi.org/10.1089/scd.2020.0046
PMid:32438891 PMCid:PMC7469698
Tűzesi Á, Kling T, Wenger A, Lunavat TR, Jang SC, Rydenhag B, et al. Pediatric brain tumor cells release exosomes with a miRNA repertoire that differs from exosomes secreted by normal cells. Oncotarget. 2017;8(52):90164.
https://doi.org/10.18632/oncotarget.21621
PMid:29163818 PMCid:PMC5685739
Pichler S, Gu W, Hartl D, Gasparoni G, Leidinger P, Keller A, et al. The miRNome of Alzheimer's disease: consistent downregulation of the miR-132/212 cluster. Neurobiol Aging. 2017;50:167-e1.
https://doi.org/10.1016/j.neurobiolaging.2016.09.019
PMid:27816213
Kim SH, Yun SW, Kim HR, Chae SA. Eosomal microRNA expression pro fi les of cerebrospinal fl uid in febrile seizure patients. Seizure. 2020;81:47-52.
https://doi.org/10.1016/j.seizure.2020.07.015
PMid:32745947
Kiltschewskij D, Cairns MJ. Post-Transcriptional Mechanisms of Neuronal Translational Control in Synaptic Plasticity. In Synaptic Plast. London: IntechOpen; 2017.
https://doi.org/10.5772/67603
Ravnik-Glavač M, Glavač D. Circulating RNAs as potential biomarkers in amyotrophic lateral sclerosis. Mol Sci. 2020;21(4):1714-24.
https://doi.org/10.3390/ijms21051714
PMid:32138249 PMCid:PMC7084402
Gao Z, Zhang J, Wu Y. TFAP2A inhibits microRNA-126 expression at a transcriptional level to aggravate ischemic neuronal injury. Biochem Cell Biol. 2021;99(4):403-13.
https://doi.org/10.1139/bcb-2020-0361
PMid:33264079
De Felice B, Guida M, Guida M, Coppola C, De Mieri G, Cotrufo R. A miRNA signature in leukocytes from sporadic amyotrophic lateral sclerosis. Gene. 2012;508(1):35-40.
https://doi.org/10.1016/j.gene.2012.07.058
PMid:22903028
T Tanito M, Sugihara K, Hara K, Takai Y. Different glaucoma types and glaucoma surgeries among different age groups. Graefes Arch Clin Exp. 2018;256(10):2013-4.
https://doi.org/10.1007/s00417-018-4058-x
PMid:29946902
Li X, Diao H. Circular RNA circ _ 0001946 acts as a competing endogenous RNA to inhibit glioblastoma progression by modulating miR ‐ 671 ‐ 5p and CDR1. J Cell Physiol. 2019;34:1-13.
https://doi.org/10.1002/jcp.28061
PMid:30663767
Uwatoko H, Hama Y, Iwata IT, Shirai S, Matsushima M, Yabe I, Utsumi J, Sasaki H. Identification of plasma microRNA expression changes in multiple system atrophy and Parkinson ' s disease. Mol Brain. 2019;22(4):1-10.
https://doi.org/10.1186/s13041-019-0471-2
PMid:31088501 PMCid:PMC6518614
Ma X, Zhou J, Zhong Y, Jiang L, Mu P, Li Y, et al. Expression, Regulation and Function of MicroRNAs in Multiple Sclerosis. Int J Med Sci. 2014;11(3):23-33.
https://doi.org/10.7150/ijms.8647
PMid:24936144 PMCid:PMC4057480
Watanabe K, Yamaji R, Ohtsuki T. Genes to Cells 5p promotes neuronal differentiation of SH- SY5Y cells Genes to Cells. Genes to Cells. 2018;27:225-33.
https://doi.org/10.1111/gtc.12559
PMid:29341475
Casalino G, Castellano G, Consiglio A, Liguori M, Nuzziello N, Primiceri D. A predictive model for microrna expressions in pediatric multiple sclerosis detection. Int Conf Model Decis Artif Intell. 2019:177-88.
https://doi.org/10.1007/978-3-030-26773-5_16

Copyright (c) 2022 Galen Medical Journal

This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution 4.0 International License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).